Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. “Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,” said Marc H.
- 03/27/2025
|
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
- The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
- 03/21/2025
|
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
- REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted.
- 03/20/2025
|
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
- HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
- 03/19/2025
|
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
- HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. "This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies," said Marc H.
- 03/11/2025
|
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
- HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
- 03/10/2025
|
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
- The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
- 03/07/2025
|
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
- Rhenium ( 186 Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium ( 186 Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications. “Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,” said Marc H.
- 03/07/2025
|
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
- 03/06/2025
|
Plus Therapeutics Announces New Employment Inducement Grants
- HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on February 28, 2025, it granted option awards to Dr. Michael Rosol, the Company's new Chief Development Officer. The Company agreed to grant these equity awards to Dr. Rosol to induce him to commence employment with the Company.
- 03/05/2025
|
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
- HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H.
- 03/04/2025
|
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
- AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered Rhenium (186Re) Obisbemeda in patients with leptomeningeal metastases (LM).
- 02/26/2025
|
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
- Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan Stein Appointed CNSide Medical Director AUSTIN, Texas, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that is has appointed Mr. Russell Bradley as the President and General Manager of its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”).
- 02/24/2025
|
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
- AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer.
- 02/20/2025
|
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
- Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas
- 12/17/2024
|
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
- Company to present ReSPECT-LM Phase 1 trial data on Rhenium ( 186 Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will present data at the 2024 San Antonio Breast Cancer Symposium, December 10-13, 2024 in San Antonio, Texas. Presentation: Title Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation (Abstract Number: SESS-2271, Presentation ID: PS14-01) Presenter Andrew Brenner, M.D.
- 12/04/2024
|
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
- AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics' lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda.
- 12/03/2024
|
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
- Single intrathecal dose of Rhenium ( 186 Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose to the CNS subarachnoid space vs. standard of care external beam radiation Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium ( 186 Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM).
- 11/25/2024
|
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
- Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases Assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform's utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell lung cancer patients with LM.
- 11/22/2024
|
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
- CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data demonstrating the utility of the CNSide CSF Assay Platform in identifying mutations of key biomarkers in the CSF and their implications in treatment selection for LM. The data will be presented at the 2024 Society for NeuroOncology (SNO) Annual Meeting November 21-24 in Houston, Texas.
- 11/21/2024
|
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2024 Earnings Call Transcript November 14, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - VP and CFO Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
- 11/16/2024
|
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium ( 186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium ( 186 Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent and upcoming business highlights. Q3 2024 RECENT HIGHLIGHTS AND MILESTONES Completed enrollment in the Phase 1 ReSPECT-GBM trial Obtained agreement from FDA to begin enrollment in the ReSPECT-LM multi-administration trial for patients with LM (IND 153715).
- 11/14/2024
|
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
- AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx , a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. “In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as SpectronRx that can deliver for us and our patients,” said Marc H.
- 11/06/2024
|
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
- AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
- 11/05/2024
|
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
- Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium ( 186 Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM Company to host an educational symposium featuring clinical experts discussing LM and Plus' recent announcements for its LM therapeutic and diagnostic programs AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting November 21-24, 2024 in Houston, Texas. Data presentations and symposium include: Presentations: Title Rhenium (186Re) Obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose escalation study and Phase 2 administered dose selection (CTNI-63) Presenter Andrew Brenner, M.D.
- 10/29/2024
|
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
- Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New York and Upper Midwest AUSTIN, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating the Company's lead asset Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma. The data were presented at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting on September 30, 2024, in Houston, Texas.
- 10/01/2024
|
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
- AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, will present data at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting September 28 - October 2, in Houston, Texas.
- 09/18/2024
|
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Marc H.
- 09/04/2024
|
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
- 08/14/2024
|
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights.
- 08/14/2024
|
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
- Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM.
- 08/13/2024
|
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
- Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium ( 186 Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM). The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado.
- 08/12/2024
|
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
- AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
- 08/08/2024
|
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
- AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, in Denver, Colorado. “This year's SNO/ASCO Metastases conference is a key opportunity for Plus to highlight advancements in our LM therapeutics and diagnostics programs,” said Marc H.
- 07/25/2024
|
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
- AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m.
- 07/02/2024
|
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
- Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller as the Company's Vice President of Medical Affairs and Medical Director.
- 06/07/2024
|
Plus Therapeutics Announces New Employment Inducement Grants
- AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company's new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr.
- 05/17/2024
|
Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Senior Vice President and Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
- 05/15/2024
|
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.
- 05/15/2024
|
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
- AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
- 05/13/2024
|
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
- Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™ ” and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda Company summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024 Call replay & transcript available via the link below AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial. “Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U.
- 05/09/2024
|
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
- Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in August 2024 Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets. During the call, President and Chief Executive Officer Dr. Marc H.
- 05/08/2024
|
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
- AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to raise up to approximately $18 million in gross proceeds, including initial upfront funding of approximately $6.5 million, and up to an additional approximately $11.5 million upon cash exercise of accompanying warrants at the election of the investors. The financing includes participation from AIGH Capital Management LLC with additional participation from new healthcare-focused institutional investors as well as certain Company insiders.
- 05/06/2024
|
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
- Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization AUSTIN, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company's clinical trial for pediatric brain cancer.
- 04/22/2024
|
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
- The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity.
- 04/09/2024
|
Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
- 03/05/2024
|
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
- Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
- 03/05/2024
|
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium ( 186 Re) obisbemeda for leptomeningeal metastases (LM)
- 03/05/2024
|
Plus Updates Financial and Cash Guidance for 2024
- Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024. Plus is currently in the second year of a Cancer Prevention and Research Institute of Texas (CPRIT) award totaling $17.8 million.
- 12/18/2023
|
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
- AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here.
- 11/15/2023
|
Penny Stocks To Buy Now? 4 To Watch Before Next Week
- Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth and upside.
- 11/03/2023
|
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
- AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to rhenium (186Re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM).
- 11/03/2023
|
Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
- 10/31/2023
|
Plus Therapeutics Announces Share Repurchase Program
- AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company's outstanding common stock. The Company intends to fund any share repurchases with available cash.
- 10/31/2023
|
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17 th ; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results
- 10/31/2023
|
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
- Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting
- 10/25/2023
|
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
- AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 10/23/2023
|
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
- AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM) .
- 09/11/2023
|
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 3:00 p.m. ET at the Lotte New York Palace in New York, NY.
- 08/30/2023
|
Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capita Operator Good afternoon, ladies and gentlemen.
- 08/14/2023
|
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
- AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 08/08/2023
|
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
- AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m. ET at the InterContinental Boston in Boston, Mass.
- 08/03/2023
|
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
- AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.
- 07/13/2023
|
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
- AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m. ET.
- 05/25/2023
|
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript.
- 04/20/2023
|
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
- Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
- 04/20/2023
|
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
- AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate as a panel presenter at the Canaccord Genuity Horizons in Oncology Virtual Conference.
- 04/18/2023
|
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023
- AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2023 financial results on Thursday, April 20, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 04/12/2023
|
Plus Therapeutics, Inc. (PSTV) Q4 2022 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - HC Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full Year 2022 Results Conference Call.
- 02/23/2023
|
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
- Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
- AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 02/14/2023
|
Plus Therapeutics, Inc. (PSTV) Q3 2022 Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2022 Earnings Conference Call October 20, 2022 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Sean Lee - HC Wainwright Brandon Carney - B. Riley Operator Good afternoon, ladies and gentlemen.
- 10/20/2022
|
Plus Therapeutics to Present at the ThinkEquity Conference
- AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.
- 10/18/2022
|
Best Penny Stocks To Buy? 3 To Watch During The Stock Market Crash
- Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
- 10/10/2022
|
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
- AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 10/06/2022
|
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
- AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace Hotel in New York City.
- 09/08/2022
|
Hot Penny Stocks To Buy For Under $1 Right Now
- Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/29/2022
|
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
- AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the Phase 1/2a ReSPECT-GBM™ dose escalation clinical trial evaluating the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France.
- 08/23/2022
|
Why Is Plus Therapeutics (PSTV) Stock Up 56% Today?
- Source: CI Photos / Shutterstock.com Plus Therapeutics (NASDAQ: PSTV ) stock is in the news Thursday as investors react to the company getting a $17.6 million grant. That Product Development Research grant comes from the Cancer Prevention and Research Institute of Texas.
- 08/18/2022
|
Cheap Penny Stocks to Buy Now? 3 To Watch in August
- Here's what you need to know about buying penny stocks on August 18th The post Cheap Penny Stocks to Buy Now? 3 To Watch in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/18/2022
|
Why Is Plus Therapeutics (PSTV) Stock Up 38% Today?
- Source: Shutterstock / PopTika Plus Therapeutics (NASDAQ: PSTV ) stock is climbing higher on Monday after the company revealed a stock buyback program. According to a press release from the company, its Board of Directors approved the repurchase of up to $2 million worth of PSTV stock.
- 08/15/2022
|
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
- AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO), being held August 12-13, 2022 in Toronto, Canada.
- 07/28/2022
|
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit
- AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and SVP will give a presentation on the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), and share updates on the U.S. ReSPECT clinical trials at the inaugural Targeted Radiopharmaceuticals Summit, organized by Hanson Wade, being held July 26-28, 2022 at the Boston Park Plaza in Boston, Massachusetts.
- 07/27/2022
|
Plus Therapeutics, Inc. (PSTV) CEO Dr. Marc Hedrick on Q2 2022 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2022 Results Conference Call July 21, 2022 5:00 PM ET Company Participants Dr. Marc Hedrick - President and Chief Executive Officer Dr. Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Michael Rabinowitz - Maxim Group Ed Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Second Quarter 2022 Results Call.
- 07/21/2022
|
Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022
- AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2022 financial results on Thursday, July, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 07/13/2022
|
Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial
- Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord. Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).
- 06/22/2022
|
Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference
- AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present virtually at the 2022 H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
- 05/18/2022
|
3 Stocks Under $1 Insiders Are Aggressively Buying
- US crude oil futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.
- 04/29/2022
|
Plus Therapeutics to Present at the 2022 Q2 Investor Summit
- AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2022 Q2 Investor Summit on Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand Central, New York, N.Y.
- 04/26/2022
|
Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022
- AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2022 financial results on Thursday, April, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 04/14/2022
|
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
- AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 02/18/2022
|
Hot Penny Stocks to Watch Right Now That Are Moving in Premarket
- These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/06/2022
|
Plus Therapeutics Expands Investigational Oncology Drug Pipeline
- Plus Therapeutics, Inc (NASDAQ: PSTV) has entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer. “The future of cancer therapy is precise targeting of tumors with the most potent cancer-killing agents while minimizing damage to normal tissues,” said Plus CEO Marc H.
- 01/06/2022
|
Best Biotech Penny Stocks to Buy Now? 3 to Watch in January
- Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/04/2022
|
Plus Therapeutics to Present at MedInvest Oncology Investor Conference
- AUSTIN, Texas, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the MedInvest Oncology Investor Conference on Tuesday, December 7th at 12:00 p.m. ET.
- 12/02/2021
|
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2021 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2021 Results - Earnings Call Transcript
- 10/21/2021
|
Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
- Patient accrual for the Phase 1 dose escalation clinical trial of 186 RNL (ReSPECT-LM) is expected in the fourth quarter of 2021
- 10/19/2021
|
Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021
- AUSTIN, Texas, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2021 financial results on Thursday, October 21, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 10/14/2021
|
Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting
- AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on Rhenium-186 NanoLiposome (186RNL) from its ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day being held November 18-21, 2021 in Boston, Massachusetts.
- 09/30/2021
|
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
- AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its Rhenium-186 NanoLiposome (186RNL) investigational radiotherapeutic for recurrent glioblastoma (GBM) at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting being held in person October 24-27, 2021 in Chicago, Illinois.
- 09/23/2021
|
Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
- AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021.
- 09/08/2021
|
Plus Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened
- The shares of Plus Therapeutics, Inc. (Nasdaq: PSTV) increased by over 20% pre-market. This is why it happened.
- 08/23/2021
|
Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
- Data shows that the administration of Rhenium-186 NanoLiposome ( 186 RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than with standard modalities
- 08/21/2021
|
Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial
- Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome ( 186 RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM)
- 08/19/2021
|
Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
- AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECT™ clinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021.
- 08/13/2021
|
PSTV Stock Price Increased 11.23%: Why It Happened
- The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased 11.23%. This is why it happened.
- 08/11/2021
|
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
- AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for the treatment of leptomeningeal metastases (LM). The data will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021.
- 08/11/2021
|
Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
- AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview during the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12th at 4:30 p.m. ET.
- 08/05/2021
|
Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement
- Global agreement covers 186 RNL manufacturing intermediate
- 07/27/2021
|
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript
- 07/22/2021
|
Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
- Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET
- 07/22/2021
|
PSTV Stock Increased Over 10% Intraday: Why It Happened
- The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 10% during intraday trading. This is why it happened.
- 07/22/2021
|
Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial
- Plus Therapeutics Inc (NASDAQ: PSTV) has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma (rGBM) has been treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort.
- 07/22/2021
|
Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021
- AUSTIN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2021 financial results on Thursday, July 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
- 07/15/2021
|
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
- AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECT™ trial, which is evaluating the Company's lead investigational drug, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).
- 06/16/2021
|
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
- AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6 th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021.
- 06/10/2021
|
Plus Therapeutics to Participate in BIO Digital Conference
- AUSTIN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.
- 06/09/2021
|
PSTV Stock: From $2.60 To $2.84 (9.23% Increase) Pre-Market Explanation
- The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) went from $2.60 to $2.84 (up 9.23%) pre-market. This is why it happened.
- 05/04/2021
|
Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
- – Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply
- 05/04/2021
|
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript
- 04/23/2021
|
Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
- Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET
- 04/22/2021
|
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
- AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021 financial results on Thursday, April 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.
- 04/08/2021
|
PSTV Stock Price Increases Over 40% Pre-Market: Why It Happened
- The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 40% pre-market. This is why it happened.
- 03/23/2021
|
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
- Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets
- 03/23/2021
|
Plus Therapeutics to Participate in Upcoming Virtual Conferences
- AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences.
- 03/03/2021
|
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript
- Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript
- 02/22/2021
|
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
- – Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –
- 02/22/2021
|
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021
- AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.
- 02/11/2021
|
Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference
- AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.
- 02/11/2021
|
Plus Therapeutics to Participate in Upcoming January Conferences
- AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences.
- 01/05/2021
|
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
- AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).
- 12/15/2020
|
Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference
- AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET.
- 12/08/2020
|
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
- AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).
- 12/01/2020
|
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
- Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy
- 11/19/2020
|
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
- Company Management and Principal Investigator of ReSPECT to Discuss Interim Data
- 11/13/2020
|
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial
- Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression
- 10/29/2020
|
